Tumor cells-specific targeting delivery achieved by A54 peptide functionalized polymeric micelles

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Achieving complete chemotherapeutic delivery to tumor cells remains a challenge in cancer therapy.
• Current targeted delivery systems, primarily relying on the enhanced permeability and retention (EPR) effect, have limited clinical success.
• There is a need for novel drug delivery systems with enhanced tumor-specific targeting capabilities.

Purpose of the Study:

• To design and synthesize a novel targeted drug delivery system for hepatocarcinoma therapy.
• To evaluate the efficacy and safety of doxorubicin-loaded targeted micelles in vitro and in vivo.
• To improve the therapeutic index of doxorubicin in treating liver cancer.

Main Methods:

• Synthesis of hepatocarcinoma-binding peptide (A54) functionalized, PEGylated stearic acid-grafted chitosan (A54-PEG-CS-SA) micelles.
• In vitro evaluation of cellular uptake in human hepatoma cells (BEL-7402) and normal liver cells.
• In vivo biodistribution studies in tumor-bearing animal models.
• Assessment of in vitro and in vivo anti-tumor efficacy and toxicity.

Main Results:

• A54-PEG-CS-SA micelles demonstrated specific internalization into hepatoma cells over normal liver cells.
• High distribution of micelles to liver and hepatoma tissues was observed in vivo.
• Doxorubicin-loaded A54-PEG-CS-SA micelles significantly suppressed tumor growth.
• Reduced systemic toxicity was observed compared to commercial doxorubicin formulations.

Conclusions:

• The A54-PEG-CS-SA micelle system offers a promising targeted drug delivery strategy for hepatocarcinoma.
• This targeted approach enhances doxorubicin accumulation in tumor tissues, leading to improved efficacy.
• The developed micelles represent a potential advancement in reducing chemotherapy-related side effects.